Immunotherapy for prostate cancer: False promises or true hope?
Immunotherapy for prostate cancer: False promises or true hope?
复制标题
DOI：
10.1002/cncr.30250
复制
发表时间：
2016-12-01
期刊：
影响因子：
6.2
通讯作者：
McNeel, Douglas G.
中科院分区：
文献类型：
--
作者：
Rekoske, Brian T.;McNeel, Douglas G.
Prostate cancer is the most commonly diagnosed cancer, and the second leading cause of cancer-related death, for men in the United States. Despite the approval of several new agents for advanced disease, each of these has prolonged survival by only a few months. Consequently new therapies are sorely needed. For other cancer types, immunotherapy has demonstrated dramatic and durable treatment responses, causing many to hope that immunotherapies might provide an ideal treatment approach for advanced prostate cancer. However, apart from sipuleucel-T, prostate cancer has been conspicuously absent from the list of malignancies for which immunotherapies have received recent FDA approval. This has left some wondering if immunotherapy will “work” for this disease. In this review we describe current immunotherapy developments, including approaches to engage tumor-targeting T cells, disrupt immune regulation, and alter the immunosuppressive tumor microenvironment. We then describe the recent application of these approaches to the treatment of prostate cancer. Given the FDA approval of one agent, and the fact that several others are in advanced stages of clinical testing, we believe that immunotherapies offer real hope to improve patient outcomes for prostate cancer, especially as investigators begin to explore rational combinations of immunotherapies and combine these therapies with other conventional therapies. Condensed Abstract: In this review we highlight the history of immunotherapeutic development for prostate cancer and many of the strategies currently being explored. We conclude that immunotherapies have promise for improving clinical outcomes, and that the greatest benefits will come as immunotherapy approaches begin to be rationally combined with other therapies.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
影响因子：
6.2
作者：
Higano, Celestia S.;Schellhammer, Paul F.;Frohlich, Mark W.
通讯作者：
Frohlich, Mark W.
影响因子：
56.9
作者：
Lee, KM;Chuang, E;Bluestone, JA
通讯作者：
Bluestone, JA
影响因子：
158.5
作者：
Kantoff, Philip W.;Higano, Celestia S.;Young, J.
通讯作者：
Young, J.
影响因子：
4.5
作者：
Emerson, Laurel;Morales, Alvaro
通讯作者：
Morales, Alvaro